Beta-blockers remain a cornerstone therapy in cardiology, demonstrating significant reductions in morbidity and mortality across various cardiovascular conditions including acute coronary syndrome and heart failure.
Since the beginning of the 1960s, beta-blockers have been number one medications in the treatment of cardiovascular diseases. A number of randomized controlled trials (RCTs) demonstrated positive effect of beta-blockers on morbidity and mortality [1]. It is difficult to overestimate the role of beta-blockers in modern cardiology. According to the results of a meta-analysis of 18 RCTs, administration of beta-blockers in patients with a risk of cardiovascular disease was associated with a reduction of the risk of stroke by 29%, coronary heart disease (CHD) by 7%, and chronic heart failure (CHF) by 29% [2]. In combination with ACE inhibitors, antiplatelet agents and statins, beta blockers helped to decrease mortality from acute coronary syndrome by 90% [3].
No takes yet. Share an insight, caveat, or question.
Романова et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: